The purpose of this study was to evaluate the contribution of SHISA3 promoter methylation to laryngeal squamous cell carcinoma (LSCC). SHISA3 promoter methylation status and expression were determined using methylation-specific polymerase chain reaction (MSP) and quantitative real-time PCR (qRT-PCR) in 93 paired LSCC and adjacent normal tissues, respectively. Furthermore, the regulatory function of the SHISA3 promoter fragment was analyzed using a luciferase reporter assay. The results reveal that there is a significant increase in SHISA3 methylation in LSCC tissues compared with corresponding nontumor tissues P=4.58E-12. The qRT-PCR results show a significant association between SHISA3 methylation and expression in LSCC P=1.67E-03. In addi...
International audienceDuring malignant transformation, the malignant cell accumulates epigenetic abn...
Head and neck cancer accounted for 3.3% of incident malignancies and 2.0% of cancer-deaths in the US...
Head and neck cancer accounted for 3.3% of incident malignancies and 2.0% of cancer-deaths in the US...
Background. Shisa3 is a novel tumor suppressor identified in lung cancer. However, its antitumor act...
Abstract Background LZTS2 (leucine zipper tumor suppressor 2), a candidate tumor suppressor gene, su...
) methylation profiles for head and neck squamous cell carcinoma (HNSCC) tumors at diagnosis and fol...
SSTR2 promoter hypermethylation is associated with the risk and progression of laryngeal squamous ce...
DNA methylation plays an important role in the etiology and pathogenesis of head and neck squamous c...
Background: Laryngeal squamous cell carcinoma (LSCC) is the second most common head and neck squamou...
International audienceDuring malignant transformation, the malignant cell accumulates epigenetic abn...
Breast cancer (BC) is the foremost cause of cancer related deaths in women globally. Currently there...
International audienceDuring malignant transformation, the malignant cell accumulates epigenetic abn...
International audienceDuring malignant transformation, the malignant cell accumulates epigenetic abn...
Growing evidence suggests that genetic and epigenetic factors, including environmental factors, cont...
PURPOSE: Hypermethylation of tumor suppressor gene promoters has been found in head and neck squamou...
International audienceDuring malignant transformation, the malignant cell accumulates epigenetic abn...
Head and neck cancer accounted for 3.3% of incident malignancies and 2.0% of cancer-deaths in the US...
Head and neck cancer accounted for 3.3% of incident malignancies and 2.0% of cancer-deaths in the US...
Background. Shisa3 is a novel tumor suppressor identified in lung cancer. However, its antitumor act...
Abstract Background LZTS2 (leucine zipper tumor suppressor 2), a candidate tumor suppressor gene, su...
) methylation profiles for head and neck squamous cell carcinoma (HNSCC) tumors at diagnosis and fol...
SSTR2 promoter hypermethylation is associated with the risk and progression of laryngeal squamous ce...
DNA methylation plays an important role in the etiology and pathogenesis of head and neck squamous c...
Background: Laryngeal squamous cell carcinoma (LSCC) is the second most common head and neck squamou...
International audienceDuring malignant transformation, the malignant cell accumulates epigenetic abn...
Breast cancer (BC) is the foremost cause of cancer related deaths in women globally. Currently there...
International audienceDuring malignant transformation, the malignant cell accumulates epigenetic abn...
International audienceDuring malignant transformation, the malignant cell accumulates epigenetic abn...
Growing evidence suggests that genetic and epigenetic factors, including environmental factors, cont...
PURPOSE: Hypermethylation of tumor suppressor gene promoters has been found in head and neck squamou...
International audienceDuring malignant transformation, the malignant cell accumulates epigenetic abn...
Head and neck cancer accounted for 3.3% of incident malignancies and 2.0% of cancer-deaths in the US...
Head and neck cancer accounted for 3.3% of incident malignancies and 2.0% of cancer-deaths in the US...